Chesterfield Special Cylinders reports a FY25 turnaround with EBITDA back in profit, a rebuilt cash balance, and strong growth outlook in defence and hydrogen sectors.
This article covers information on Chesterfield Special Cylinders Hdgs.
LON:CSCChesterfield Special Cylinders Holdings (AIM: CSC) has posted a clean turnaround in FY25. Revenue rose 12% to £16.6 million, gross margin expanded to 39%, and Adjusted EBITDA swung to a £0.8 million profit from a £0.9 million loss. The balance sheet has been reset too: cash closed at £2.1 million with nil borrowings, helped by the October 2024 sale of the PMC division. Management says earnings came in ahead of market expectations and enters FY26 with a robust defence order book and growing hydrogen pipeline.
There is still a statutory loss before tax of £0.8 million, but the direction of travel is positive, and the second half did the heavy lifting. Contract revenues in FY26 are “heavily” second-half weighted, so timing will matter again.
| Metric | FY25 | FY24 | Why it matters |
|---|---|---|---|
| Revenue | £16.6m | £14.8m | Back to growth, driven by defence and lifecycle services |
| Gross profit (margin) | £6.4m (39%) | £4.9m (33%) | Margin rebuild shows pricing and mix improving |
| Adjusted EBITDA | £0.8m | £(0.9)m | Operational profitability restored |
| Adjusted operating profit | £43,000 | £(1.7)m | Near breakeven at operating level |
| Reported loss before tax | £(0.8)m | £(2.7)m | Loss narrowing |
| Basic loss per share | 1.6p | 6.1p | Improving trend |
| Adjusted basic loss per share | 0.0p | 4.7p | Near breakeven on an adjusted basis |
| Cash | £2.1m | £0.1m | Balance sheet flexibility restored |
| Borrowings | Nil | £1.0m | Debt repaid post-PMC sale |
| Order intake | £23.4m | £13.1m | Strong demand underpinning visibility |
| Order book (period end) | £16.3m | £9.5m | Good FY26 coverage |
| Defence revenue | £12.8m | £11.1m | 15% growth, overseas contracts key |
| Hydrogen revenue | £2.6m | £1.7m | Highest on record |
| Integrity Management revenue | £4.8m | £2.4m | Record year for lifecycle services |
Definitions: Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation and exceptional costs. Integrity Management is CSC’s in-situ lifecycle support service that inspects, tests and recertifies safety-critical pressure systems.
Defence delivered £12.8 million, up from £11.1 million, as overseas contracts offset the wind-down in some UK newbuild milestones. Order intake in defence more than doubled to £19.1 million, taking the defence order book to £14.6 million. Notable programmes span the Royal Australian, Royal Canadian, US and Spanish navies, plus strong UK Integrity Management work.
Importantly, management points to further overseas defence awards expected in Q1 2026. Over the medium term, AUKUS SSN-A activity is expected from FY27, with opportunities in the US submarine programme from FY28.
Hydrogen revenue hit a record £2.6 million, reflecting in-factory lifecycle work and initial milestones for the bp Aberdeen Hydrogen Hub. The UK’s Hydrogen Allocation Rounds (HAR) remain the key catalyst: ten HAR1 projects approved and 27 HAR2 shortlisted. A major HAR1 award slipped into Q1 2026, and first HAR2 awards are expected within FY26 for FY27 delivery.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
65 viewsLikes
No ratings yet
CSC also signed a cooperation agreement with a leading Type 4 composite cylinder manufacturer to supply lightweight hydrogen road trailers, targeting growing UK demand from FY27. That broadens product capability from Type 1 steel into composite trailer solutions.
Lifecycle services revenue doubled to a record £4.8 million, driven by a peak in UK naval deployments. CSC is in advanced discussions with several European navies, with European deployments expected during FY26. This is a high-value, recurring service line that smooths lumpier newbuild revenue cycles.
The order book closed at £16.3 million, backed by £23.4 million of FY25 intake. Management guides to “significant earnings growth” in FY26, weighted to H2. Beyond that, they see further revenue and earnings growth from FY27 as UK and overseas defence newbuilds expand and UK hydrogen projects finally scale up.
CSC reconfirms its mid-term targets first set out in 2024:
FY25 progress included the PMC divestment (no further cash consideration expected), overseas defence wins, record hydrogen revenue, and the Aberdeen Hub contract. Central costs were reduced to £0.8 million from £1.7 million, helping margins.
On the flip side, the balance sheet is much stronger: cash of £2.1 million, nil borrowings, and net cash of £1.8 million including leases. That gives room to manage phasing and working capital as the order book converts.
CSC has moved from stabilisation to execution. The company exited FY25 with positive Adjusted EBITDA, improved gross margins, and a reset balance sheet after the £4.4 million PMC sale proceeds. Defence exposure is broadening overseas, while the hydrogen business is finally starting to contribute with concrete UK catalysts in FY26 and a road trailer push from FY27.
Negatives are clear: statutory losses persist, H2 weighting introduces delivery risk, and customer concentration remains elevated. But with an order book of £16.3 million, defence order intake more than doubled, and lifecycle services at record levels, the operational platform looks better set than it has for several years.
I view FY25 as a credible pivot. Margin gains, cost discipline and cash generation are all moving the right way. The defence pipeline feels tangible, spanning Australia, Canada, Spain and the US qualification path, while hydrogen has visible UK policy support through HAR1/HAR2 despite delays.
Key near-term watch items: the Q1 2026 HAR1 award, further defence wins in Q1 2026, and confirmation that H2-weighted FY26 deliveries land as planned. If those fall into place, CSC should move closer to its mid-term goals and shift investor focus from survival to scale and margin expansion.
Dividend remains off the table for now (not disclosed), which is sensible while the company consolidates the turnaround and invests in growth.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.